Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0146
OPINION
|
Cetuximab: Explaining resistance and disappointing new results
|
Prof. Dr. Med Christof Hottenrott, M.D.
|
Affiliation: Prof. Dr. Med Christof Hottenrott, Chirurgische Klinik St. Elisabethenkrankenhaus Ginnheimer Straße 3, 60487, Frankfurt . |
ABSTRACT
Cetuximab – a monoclonal antibody against EGFR- has been approved for the treatment of KRAS wild-type metastatic colorectal cancer (mCRC). However, new results from phase III randomized controlled trials (RCTs) presented in the 2010 ASCO meeting arise serious concerns on the clinical utility of adding cetuximab to standard chemotherapy. For the first time results from a large RCT with cetuximab treatment in the adjuvant setting, become available. In the metastatic setting, the results of a new RCT are in contrast with previous RCTs that had showed an overall survival benefit with cetuximab in KRAS wild-type mCRC. Can these RCTs be considered as practice-changing studies? How can be explained the resistance and failure of cetuximab in both adjuvant and metastatic setting of CRC?
(Citation: Gastric & Breast Cancer 2011; 10(1): 25-29)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
